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Abstract  
Vitamin D related research continues to expand and theorise regarding its involvement in obesity, 
as both hypovitaminosis D and obesity strike in pandemic proportions. Vitamin D plays an important 
role in immune system through Vitamin D Receptors (VDR), which are transcription factors located 
abundantly in the body. Due to this characteristic, it is potentially linked to obesity, which is a state 
of inflammation involving the release of cytokines from adipose tissue, and exerting stress on other 
organs in a state of positive energy balance. Research trials in the past couple of years and 
systematic reviews from SCOPUS and MEDLINE will be discussed. The role of Vitamin D 
throughout the lifespan (from fetal imprinting until older age), and in various other obesity mediated 
chronic conditions shall be highlighted. Various mechanisms attributed to the inverse relationship of 
Vitamin D and obesity are discussed with research gaps identified, particularly the role of 
adipokines, epigenetics, calcium and type of adipose tissue. 
 
 
 
 
 
 
 
 
Introduction 
 
This study reviews articles available on 
PUBMED, Scopus and Google using the following 
search keywords: (Vitamin D OR Ergocalciferol OR 
Cholecalciferol) AND (Leptin/ adiponectin/ VDR/ 
inflammation/ adiposity/ body fat/ weight). The search 
was limited to articles in the English language until 
June 2016. Selected articles were also used to 
identify further relevant studies. Most relevant 
research articles were included; usually, review 
articles and meta-analysis to present an analysed 
picture of clinical trials regarding relevant information. 
Vitamin D is a micronutrient that is 
categorically non-essential due to the endogenous 
production in the body with the aid of specific 
ultraviolet rays, but it has now become an essential 
component of diet as Vitamin D deficiency now 
engulfs the world as a pandemic [1]. This idea was 
established many years ago as Vitamin D inadequacy 
was observed even among people living closer the 
equator [2]. Hence, regulations directing fortification of 
food is either implemented or are under consideration 
[3]. In the 2011 conference of Institute of Medicine 
(IOM), the Recommended Dietary Allowance (RDA) 
(average daily level of intake sufficient to meet the 
nutrient requirements of nearly all (97%-98%) healthy 
people) for Vitamin D was set at 600 IU/d for ages 1-
70 years and 800 IU/d for ages 71 years and older [4]. 
According to the Institute of Medicine (IOM) 
Committee, the scientific evidence supports the key 
role of Vitamin D in skeletal health and extra-skeletal 
health; however, the extra-skeletal health outcomes 
are not yet consistent to establish a cause-and-effect 
relationship [4]. Doses to treat and/or maintain Vitamin 
D status are still subjective and research studying the 
needs across different life spans and conditions 
continue. Vitamin D status now conjoins many other 
health conditions after the discovery of Vitamin D 
binding proteins and their receptors in many tissues 
[5]. Vitamin D binding receptors (VDR) are 
transcription factor responsible for extensive biological 
responses. It is shown to play a role in cell 
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proliferation inhibition, cell maturation, immune 
system, and possibly colonic, breast and prostate 
cancer [6]. Vitamin D status is influenced by sun 
exposure, adiposity, body composition, race/ethnicity, 
and genetic factors, but these need elucidations 
through research, as suggested by IOM [6]. 
Vitamin D deficiency has been historically 
defined and recently recommended by the Institute of 
Medicine (IOM) as a 25(OH)D of less than 20 ng/ml. 
Vitamin D insufficiency has been defined as a 
25(OH)D of 21–29 ng/ml. Vitamin D deficiency results 
in abnormalities in calcium, phosphorus, and bone 
metabolism. Specifically, vitamin D deficiency causes 
a decrease in the efficiency of intestinal calcium and 
phosphorus absorption of dietary calcium and 
phosphorus, resulting in an increase in PTH levels. 
Secondary hyperparathyroidism maintains serum 
calcium in the normal range at the expense of 
mobilising calcium from the skeleton and increasing 
phosphorus wasting in the kidneys. The PTH-
mediated increase in osteoclastic activity creates local 
foci of bone weakness and causes a generalised 
decrease in bone mineral density (BMD), resulting in 
osteopenia and osteoporosis. Phosphaturia caused by 
secondary hyperparathyroidism results in a low 
normal or low serum phosphorus level. This results in 
an inadequate calcium-phosphorus product, causing a 
mineralisation defect in the skeleton. This results in an 
inadequate calcium-phosphorus product, causing a 
mineralisation defect in the skeleton [7]. 
A major health issue linked with Vitamin D is 
the growing obesity rate. World Health Organization 
states that in 2014 more than 1.9 billion adults were 
overweight, of which 600 million were obese. 
According to the Global Burden of Disease report of 
USA, the potentially avoidable risk factors to rising 
disease burden included high BMI and physical 
inactivity for the healthy years lost [8]. Healthy years 
measure the expected number of years a person of a 
certain age could live without disability or be free of 
any activity limitation. Despite increased levels of 
sufficient physical activity in male and female, only 9 
countries experienced a decline in obesity rate in the 
United States (with statistically insignificant results) 
compared to increment in the rest of the counties in 
obesity during 2001 and 2009 [8]. Systematic analysis 
to study Global, regional and national prevalence of 
overweight and obesity in children and adults 1980-
2013 did not report any significant decline in rate over 
the past 33 years, but only a slowdown in increase 
rate of overweight and obesity was observed just in 
developed countries [9]. This is not satisfactory, as it 
indicates that an increasing obesity trend endures in 
other countries. This demands special attention from 
the public health sector to search and address socio-
economic implications in maintaining Vitamin D. To 
explain the deficiency of this fat-soluble vitamin in 
people with excessive adipocytes, the following 
possible mechanisms have been suggested: lower 
dietary intake; altered behavior that reduces 
cutaneous synthesis, reduced synthetic capacity, 
reduced intestinal absorption, altered metabolism, and 
sequestration in adipose tissue [10,11]. However, 
extensive research is needed to establish a cause-
effect relationship and explain these factors under 
various conditions, because Vanlint concluded in his 
review that the evidence for vitamin D affecting fat 
mass and distribution is not yet compelling, and it is 
difficult to determine which effects are due to vitamin 
D itself and which are mediated via calcium when 
based on evidence from in vitro studies [11].  
Finally, this article highlights how these public 
health issues of Vitamin D with its immune-related 
properties are associated with obesity, which is a 
state of low-grade inflammation. Various gaps 
identified by IOM committee is briefly reviewed, such 
as, non-skeletal health outcomes, epigenetic role, 
physiology and pathways of Vitamin D [4]. 
Researchers have previously reviewed data on this 
topic, [12, 14, 15], but due to constant addition of 
knowledge in this area we considered updating. 
Unlike some previous articles, we have concentrated 
on discussing Vitamin D and inflammatory properties 
in obesity, and further supplemented suggested 
mechanisms with clinical studies. 
 
 
Obesity, a state of low-grade 
inflammation 
 
Ectopic fat storage, due to overflow from 
adipose tissues upon fat overloading leads to the 
formation of foam cells from macrophages that engulf 
fat droplets during transportation or storage. 
Macrophages phagocytize lipid droplets in weight loss 
from adipocytes that could describe basic 
inflammatory nature of adipocytes. Hyperplasia and 
hypertrophy of adipocytes can cause mitochondrial 
and endoplasmic stress, which during fat overloading 
releases additional inflammatory cytokines other than 
adipokines, attracting more macrophages. During 
adipocytes hypertrophy TNF-α (Tumor Necrosis 
Factor- alpha), IL-6 (Interleukin-6), IL-1β (Interleukin-1 
Beta), PG-E2 (Prostaglandin E2) expression is 
induced, adipocytes die and neutrophils, monocytes 
and T-Cells are persistently activated. CRP is also 
enhanced in the liver to respond to inflammatory 
cytokines, amplifying the cytokines pro-inflammatory 
effect. Hyperplastic adipocytes also induce genes 
TNF-α, interleukins (IL)-1, IL-6, monocyte 
chemoattractant protein-1 (MCP-1), and plasminogen 
activator inhibitor-1 (PAI-1) due to hypoxia from 
clustered formation, which are distant from the 
vasculature. Macrophages embedded in adipocytes 
phagocytize lipid droplets and engulf dead adipocytes 
that burst from high lipid accumulation, releasing 
reactive oxygen species and inducing further cellular 
stress [16]. The unfolded protein response (UPR) to 
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cope with Endoplasmic Reticulum (ER) stress 
promotes NF-κB (nuclear factor kappa-B) and JNK (c-
Jun N-terminal kinases) inflammatory pathways due to 
increased protein demand such as in hyperglycemia, 
or during accumulation of misfolded protein. 
Excessive nutrient influx increases superoxide 
production and reactive oxygen species by 
mitochondria. The down-regulation of autophagy in 
the liver of lipid droplets in hepatocytes associated 
with obesity leads to accumulation of triglyceride, ER 
stress and Insulin resistance [17]. 
Visceral or subcutaneous fat in obesity-
related inflammation is still questionable due to 
variability in results. A study investigating 
concentrations of pro-inflammatory enzymes 
presented higher concentration of IL-6 and IL-15 
(Interleukin-15) in Subcutaneous Adipose Tissue 
(SAT) synthesis compared to Visceral Adipose Tissue 
(VAT). However, obesity was associated with VAT, 
since IL-6 and IL-15 were significantly more in obese 
individuals compared to normal-weight ones, 
whereas, the cytokines difference was not significant 
between two groups in SAT related cytokines 
expression [18]. On the other hand, some studies do 
suggest increased pro-inflammatory cytokines 
expression in SAT compared to VAT proposing its 
contribution to meta-inflammation [18, 19]. In 
conclusion, visceral fat compared to subcutaneous fat 
may cause metabolic abnormalities by secreting 
inflammatory adipokines, such as interleukin, tumour 
necrosis factor-α, macrophage chemoattractant 
protein-1, and resistin, which induce insulin resistance 
and diabetes and Vitamin D metabolic abnormalities. 
 
 
Role of Vitamin D in obesity and 
suggested mechanisms 
 
Research to explore the relationship between 
Vitamin D and obesity gains interest, because studies 
investigating obesity (a state of low-grade 
inflammation) and Vitamin D (with its role in immunity) 
indicate potential links. Many studies report changes 
in Vitamin D status with BMI changes. A change in 
serum Vitamin D levels as a function of 
adiposity/weight loss was noted over 1-2 years [20, 
21]. An inverse relationship between Vitamin D and 
BMI was recognised in Mendelian randomization 
analysis, [22] and a link with abdominal visceral or 
subcutaneous adipose tissue was also recognised 
[23, 24].
 
In a meta-Analysis of observational studies 
up to April 2014 in PubMed/Medline, Vitamin D 
deficiency was prevalent in obese subjects 
irrespective of age, latitude and cut-offs defining 
vitamin D deficiency [14].
 
Another meta-analysis of literature focusing 
on the last 5 years proposed various mechanisms to 
discern body weight and Vitamin D relationship, which 
include: Vitamin D Receptor (VDR) polymorphism 
shown in transgenic mice and its overexpression in 
adipocytes that led to fatty acid β-oxidation, lipolysis 
and reduced energy metabolism; increased 
parathyroid hormone levels in Vitamin D deficiency 
that can increase adiposity by influx of calcium into 
adipocytes promoting lipogenesis; Vitamin D as 
“essential factor” in leptin depletion which may 
contribute to increased appetite and obesity in Vitamin 
D deficient conditions; and outdoor activity, food 
intake and exercise which can also influence Vitamin 
D levels as confounding factors [25].  
Adipokines relationship with Vitamin D is 
studied due to their role in obesity. In vitro leptin, 
secretion by adipose tissue is powerfully inhibited by 
Vitamin D deficiency [12]. Although clinical trials 
showed an increase in serum leptin with Vitamin D 
supplementation, [26, 27] the clinical significance 
remains to be asserted [12, 28]. A significant effect of 
Vitamin D supplementation on adiponectin and leptin 
was not observed in a meta-analysis of 9 Randomized 
Controlled Trials (RCT) [29]. Serum changes in 
Vitamin D were significantly associated with plasma 
leptin levels, independent of plasma adiponectin 
concentrations. Further larger clinical trials and meta-
analysis to effectively review these adipokines, 
especially focusing on obesity, are needed, as more 
meta-analysis could not be found.  
The dose-response relationship between 
serum Vitamin D levels have changed and BMI 
showed a quadratic curve in a research involving 
various Vitamin D3 doses that suggested rate-limiting 
mechanism to avoid excessive formation of 1,25-
(OH)2D3 (the active metabolite) [30]. The dose-
response curves, although parallel, were noted for 
their difference between the curves, which was 
approximately 17.5 nmol/L lower for obese subjects 
compared to normal ones, and approximately 
12.5nmol/L lower levels in overweight compared to 
normal-weight subjects. Extracellular pool size was 
suggested as the potential factor in this discrepancy 
rather than fat [29]. 
Vitamin D-metabolizing enzymes are 
expressed differently in Adipose tissue as well. There 
was decreased expression of the 25-hydroxylase 
CYP2J2 and the 1α-hydroxylase CYP27B1 (which 
converts 25(OH)D3 to the active 1,25(OH)2D3) in 
Subcutaneous adipose tissue, and increased 
expression of CYP24A1 (which inactivates calcitriol 
binding and activating VDR) after weight loss [30]. 
Calcium-sensing receptors (CaSR) gene and 
protein expression were found similar in white adipose 
tissue of obese and control mice group. Obese group 
had lower serum vitamin D and amino acid 
concentrations, and significantly higher serum 
triglyceride (TG), total cholesterol (TC), low-density 
lipoprotein-cholesterol (LDL-C), TNF-α, IL-6 and PTH 
levels, which suggests that Calcium-sensing receptors 
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function through allosteric regulation [31]. CaSR 
elevates pro-inflammatory cytokines in adipose tissue 
and decreases cyclic AMP, protein kinase An activity, 
hormone-sensitive lipase and adipose triglyceride 
lipase that are key players in the lipolytic pathway 
[32].
 
Low Calcium-induced 1,25-di(OH)2D3 secretion 
upregulates CaSR expression in adipose tissue, 
which is followed by an increase in [Ca2+] and 
reduced lipolysis, and possibly lipogenesis finally 
yielding fat accumulation in adipocytes. It was shown 
that higher BMI shows a greater increase in CaSR 
protein and thus more pro-inflammatory cytokines 
secreted from obese tissue [33]. 
 
 
Studies in relationship to Vitamin D and 
obesity in general population 
 
Obesity in adults is not only of concern for 
their reduced productivity in life but it may also affect 
new lives. Observational studies and animal studies 
now propose and explore the mechanism about how 
maternal BMI and offspring adiposity from an early 
age are independently associated, and how in-utero 
environmental exposures increase susceptibility 
to obesity and are related to cardiometabolic disorders 
in later life [34, 35].
 
An increased risk of prenatal and 
early postnatal overweight in offspring (1
st
 year of life) 
was found, which was attenuated by 4 years of age 
[36]. Vitamin D status during pregnancy could have an 
epigenetic role since it is not only pivotal in maternal 
skeletal maintenance and fetal skeletal development, 
but it could influence fetal “imprinting”, which can 
affect chronic disease susceptibility soon after birth 
[37]. Decreased placental expression of VDR in the 
placenta may be a contributing factor to the pathology 
of idiopathic FGR (Fetal Growth Restricted)-affected 
pregnancies [38]. Maternal vitamin D deficiency during 
pregnancy was associated with impaired lung 
development in 6-year-old offspring; neurocognitive 
difficulties at the age of 10, an increased risk of eating 
disorders in adolescence, and lower peak bone mass 
at the age of 20 after relevant covariates were 
adjusted. Randomised controlled trials with long-term 
follow-up of offspring are required to examine 
beneficence for offspring and to determine the optimal 
level of maternal serum 25(OH)D for fetal 
development [39]. 
Optimal Vitamin D level is also essential from 
the adolescent years until the old age that is needed 
for health benefits. Serum Vitamin D levels decline 
with puberty onset, and holds a higher risk for obesity, 
and much greater for Insulin Resistance in pre-
pubertal children with suboptimal Vitamin D serum 
levels [40, 41]. Hypovitaminosis D in overweight or 
obese adults is registered in many studies, usually 
accompanied with other health conditions.
13
 Mice on 
high-fat diet and low-fat diet was treated with calcitriol 
to demonstrate its effectiveness in reducing obesity-
associated renal abnormality. Suggested mechanism 
was through reduction of cytokines, such as Toll-like 
Receptors (TLR) that are down-regulated by Vitamin 
D, hence reducing Interleukin-6 (IL-6) or by preventing 
abnormal growth of parathyroid hormone (PTH). The 
lipid droplets were found to be in a degenerative stage 
in mice fed High-Fat-Diet (HFD) with calcitriol 
treatment, which showed a causal relationship 
between calcitriol intake in renal tubules causing 
structural changes under HFD conditions [42]. A study 
that included people above 65 years of age suggested 
an increased risk of vitamin D deficiency in overweight 
and higher body fat percentages [43]. As previously 
mentioned, studies also support an inverse 
relationship between weight loss and Vitamin D serum 
changes. This is shown to be effective in eliminating 
obesity-related inflammation since significant 
reductions in levels of IL-6 were noted with 
intervention combining Vitamin D3 supplementation 
and weight-loss program [44]. Low serum 25(OH)D 
was found to be significantly associated with high 
serum IL-6 in overweight/obese children and with 
increased hs-CRP in obese children [45]. 
1,25(OH)2D3 is also found to have a strong inhibitory 
effect on NFκB signalling in human adipocytes [46]. 
On the contrary, a meta-analysis conclusive of 13 
RCT suggests that Vitamin-D supplementation does 
not affect inflammatory markers: CRP, TNF-a, IL-6 in 
overweight or obese subjects [47]. Some studies do 
not support any link between Vitamin D 
supplementation and obesity. Supplementation 
with vitamin D showed no effect on adiposity 
measures in adults [48]. An increase in serum levels 
of 25OHD or other inflammatory markers was not 
observed in overweight and obese youths with 
150,000IU supplemented every 3 months, which 
demands investigation regarding potential dosage and 
frequency,
 
[49]
 
since another trial with dosage as low 
as 400IU up till 4800IU daily yielded serum changes 
when administered for 12 months [50]. 
 
 
Role of Vitamin D in other obesity 
mediated diseases 
 
Chronic diseases are usually linked with 
obesity, which has been further explored in relation to 
Vitamin D status or to investigate the effectiveness of 
supplementation in attenuating related symptoms. 
Visceral obesity has been also found to be related 
with low levels of Vitamin D [51]. Visceral obesity is 
also highly correlated with Non-Alcoholic Fatty Liver 
disease (NAFLD) thus it is expected that Vitamin D is 
also related with NAFLD. A recent study in adults 
demonstrated the strong link between vitamin D and 
NAFLD [52]. The authors examined a total of 1081 
adults and concluded that low vitamin D levels were 
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highly associated with NAFLD independent of visceral 
obesity in subjects with Diabetes or insulin resistance 
[52]. BMI was also strongly associated with plasma 
25- hydroxy Vitamin D, [25(OH)D] and PTH 
concentrations with possible influence of plasma 
25(OH)D in the pathogenesis of hypertriglyceridemia 
and atherogenic dyslipidemia through inflammation, 
because the association disappeared when uCRP 
(ultrasensitive C-Reactive Protein) was introduced as 
covariable [53]. 25(OH)D low levels and unfavourable 
lipid patterns have been also found in children [54]. 
No effect on β-cell function or insulin action in obese 
non-diabetic adolescents was observed upon 
administration of Vitamin D3 supplementation [55]. A 
systematic review provides evidence of the 
insignificant effect of supplementation with vitamin D 
on glucose and insulin metabolism in overweight and 
obese individuals but a positive influence on the 
serum concentration of 25(OH)D [47]. Serum 
25(OH)D level in diabetic patients (Type 2) was found 
to be inversely correlated with monocyte adhesion to 
endothelial cells. 1,25(OH)2D3 suppressed ER stress, 
[56] and promoted M1-predominant phenotype with 
lower endothelial adhesion. Vitamin D suppresses 
both subsets of monocytes, with M1 predominant, 
however, M1 is involved in advanced plaques 
compared to M2 in early stages in simple terms [57]. 
Real paradigms might be more complex and needs 
further research. A decrease in systolic blood 
pressure and adiposity in middle-aged subjects after a 
weight-loss intervention was observed with an 
increase in plasma 25(OH)D level [58]. Lower 
inflammatory profile, better insulin sensitivity, higher 
Vitamin D levels and IGF-1 (Insulin-like Growth 
Factor-1) in lean mass of obese patients recorded in 
the study suggest physical activity programs potential 
to create a better metabolic profile [59]. Hence, 
special programs to support a lifestyle that incorporate 
dietary changes and physical activity programs can be 
used to attain better Vitamin D levels with a range of 
other health benefits. 
In addition, visfatin has been recently found to 
be associated with Vitamin D levels. Visfatin is a new 
adipokine involved in several processes. Visfatin plays 
an important role in inflammatory processes [60]. In a 
very recent study [61], the authors examined 50 
patients with chronic hepatitis with elevated visfatin 
levels. After administration of vitamin D3 (15,000 
IU)/weekly, the patients’ visfatin levels were 
significantly reduced after a 12, 14, and 48-week 
period compared with the baseline data. The 
researchers concluded that Vitamin D 
supplementation may offer beneficial effects in 
reducing inflammation in these patients. More studies 
though are needed to elucidate these optimal effects. 
 In conclusion, the latest research on Vitamin 
D deficiency and obesity pandemic supports the role 
for Vitamin D in prevention and occurrence of obesity. 
Hence, public health sector needs to address the 
implying socio-economic aspects influencing Vitamin 
D status in order to prevent the burden of the disease 
which the possibly an outcome of Vitamin D 
deficiency. The adipokines secretion and inflammatory 
cytokines expression are importantly linked to Vitamin 
D metabolism. However, the mechanisms need 
further elucidation, as research is both equivocal and 
inadequate to establish a direct relationship in some 
cases. The role of visceral fat is stronger compared to 
subcutaneous fat in inflammation, related to obesity. 
The clinical trials identified in this paper usually 
involve Vitamin D supplementation in attaining 
sufficient Vitamin D levels, which indicates the need 
for trials to determine if same effects of Vitamin D can 
be observed with dietary sources too, as it is 
imperative in deciding on fortification of food across 
different socio-economic groups. 
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